Home > Healthcare > Pharmaceuticals > Finished Drug Form > Anti-Obesity Drugs Market

Anti-Obesity Drugs Market Share

Report ID: GMI10074
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Anti-Obesity Drugs Market Share

The anti-obesity drugs sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovations such as combination therapies, peptide-based therapies, novel targets, gene-based therapies, and microbiome modulation. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Anti-Obesity Drugs Market Companies

Some of the eminent market participants operating in the anti-obesity drugs industry include:

Arena Pharmaceuticals, Inc.
AstraZeneca PLC
Boehringer Ingelheim International GmbH
Currax Pharmaceuticals LLC
Eli Lily & Co
F. Hoffmann-La Roche Ltd.
Gelesis
GlaxoSmithKline plc
Merck & Co., Inc.
Novartis AG
Novo Nordisk A/S
Orexigen Therapeutics, Inc.
Pfizer Inc.
Rhythm Pharmaceuticals, Inc.
Vivus, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Anti-obesity drugs industry was valued at USD 5.6 billion in 2023 and will exhibit 27% CAGR from 2024 to 2032, attributed to the rising prevalence of obesity worldwide, increasing awareness of the health risks associated with obesity, and advancements in drug development.

Anti-obesity drugs industry from the prescription drugs segment recorded USD 4.1 billion in 2023, owing to the effectiveness and reliability of prescription medications in managing obesity.

North America anti-obesity drugs industry size will reach USD 21.9 billion by 2032, driven by the high prevalence of obesity, robust healthcare infrastructure, and significant investments in R&D.

Prominent players operating in anti-obesity drugs industry are Arena Pharmaceuticals, Inc., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Eli Lily & Co, F. Hoffmann-La Roche Ltd., Gelesis, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, and Novo Nordisk A/S, among others.